TRANSCRIPT TO FOLLOW
The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.
Morningstar fund analyst Randal Goldsmith picks three multi-asset funds that deploy alternativ...
Looking for long term growth? Value stocks will outperform in 2017, according to Fidelity's Ni...
Looking to add some precious metal to your investment portfolio? Gold can provide a buffer in ...
Weak brand momentum is exacerbated by industry slowdown, but shares remain undervalued
The European 'GRANOLAS' stocks are reporting their second quarter earnings. Here’s what our analy...
Mining companies are operating in a challenging environment but could now be the time to top up o...
THE WEEK: Morningstar columnist Rodney Hobson provides two pieces of advice to George Osborne, an...
Businesses that have competitive advantages within their industry are good candidates for dividen...
Morningstar reveals the top 10 best performers over the last five years
Morningstar OBSR reveals the top funds for investors seeking exposure to European equities
The bank also announced a deal with Metro Bank, raised its guidance, and increased its dividends
With revenue growth, increased operating margins, but a high valuation, here’s what we think of N...
We'll be watching iPhone revenue, gross margins, and services growth when Apple reports its earni...
Despite growth, Morningstar's Fair Value Estimate for the consumer goods giant stock is unchanged
Morningstar analysts think the UK's biggest company has a well-positioned broad drug portfolio wh...
Security Name | Price | Change (%) | Morningstar Rating |
---|---|---|---|
Janus Henderson European Sel Opps I Acc | 2,865.92 GBP | -2.52 | ![]() |